🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

PCP leader, Eugene Wright, Jr, notes that biomarker-based risk assessment tools may provide the greatest opportunity to align providers with large health systems (when it comes to the care model for T2D patients with CKD). Here's why.

Don't wait for symptoms to strike! Early risk assessment for kidney disease is crucial. By catching issues in their infancy, we can take proactive steps to maintain kidney health and prevent complications down the road. #ckd #T2D #earlydetection bit.ly/3QSasKS

Some other countries focus more on early testing/ diagnosis of chronic kidney disease than the U.S. Although there are costs associated with addt'l testing, there is also a cost benefit of doing so. Hear more in today's video with Dr. Eugene Wright, Jr. renalytix.com/videos/#other-…

Why are exciting places to travel and CKD in the same sentence? In our conversation with Dr. Wright re: how different countries focus on early-stage diagnosis/ treatment of CKD, we went off the rails. It turned into this mini travel podcast. Fun to watch. renalytix.com/videos/#around…

This Week At ASN: don’t miss Dr Joji Tokita from Mount Sinai Health System, for Meet the PI, on Fri. 11/3, 1:30 – 2:30, Renalytix Booth 617. He’ll discuss improving CKD outcomes in a large urban health system and share RWE assoc. with the KidneyIntelX early-stage, risk assessment test.

This Week At ASN: Save Sat., 11/4 from 11:30 – 1:30. We’ll have Hiddo Jan L Heerspink, Matthias Kretzler and Peter Rossing, MD at Renalytix Booth #617 discussing Prime-CKD, which uses a biomarker-based strategy to personalize/optimize therapeutic treatment to slow CKD progression.

STILL UNDER CONSTRUCTION: Renalytix Booth #617 is still under construction, but we couldn't wait to give a little sneak peek. See you there.

3-day countdown to Prime-CKD. Help us spread the word for this one-of-a-kind session re: the power of biomarkers to mitigate CKD progression. Peter Rossing Matthias Kretzler Steven Coca Katherine Tuttle American Society of Nephrology

TODAY! Proud of one of our co-founders, Girish Nadkarni, who will speak about AI & its promise to complement AKI Care. Learn about the history of AI in medicine and kidney disease and potential pitfalls. RM 201, 10:30 – 11. Steven Coca Icahn School of Medicine at Mount Sinai Mount Sinai Health System Barbara T. Murphy Mount Sinai Div. of Nephrology

WELCOME. Members of our Executive Team, from left to right, O. James Sterling (CFO), James McCullough (CEO), Thomas McLain (President), Howard Doran (CBO) welcome you to Renalytix Booth 617. They're ready to talk to you about all things KidneyIntelX, including our robust evidence

Gold Sponsor Renalytix is turning the tide in kidney care with early identification and treatment. 🌟 #TAHP2023

A SPECIAL REAL WORLD EVIDENCE PREVIEW: Tomorrow, Friday at 1:30 at booth #617, you will want to attend this discussion about how implementing KidneyIntelX, an early-stage risk assessment test, in DKD patients, helped improve care and outcomes at a large health system.

We have a large crew representing at the world's biggest nephrology event. We're all on hand to talk about our collective fight to eradicate kidney disease and how one simple blood test - KidneyIntelX - may provide one of the answers.

TODAY! Booth 617. 1:30. You won't want to miss it. After all, we're talking real world evidence with the PI.

TODAY! Saturday, 11/4. In just a few hours. Learn about our work with PRIME-CKD, which aims to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with CKD.

Back from ASN. We found the sessions thought-provoking and the discussions invigorating. We shared Renalytix news, which included receiving FDA De Novo Marketing Authorization for kidneyintelX.dkd and our partnership in Prime CKD. Some of our partners in the pic below.

We celebrate Katherine Tuttle, MD, recent winner of the 2023 John P. Peters Award, which recognizes individuals who have made substantial research contributions to the discipline of nephrology. We share her calling and passion to improve care at the intersection of T2D/CKD.

Can one simple blood test help slow progression of chronic kidney disease and improve type 2 diabetes control in just 12 months? Yes it can. We just proved it (again, just like we proved it with our 6 month data). See data here: renalytix.com/new-published-…

We support World Kidney Day. We also believe in action 365 days of the year. Via our KidneyIntelX™ testing technology, we id adult patients with T2D & CKD stages 1-3b who are at risk for progressive decline in kidney function which can significantly improve patient outcomes.

The progression of CKD can occur at all stages. If we understand which patients are at higher risk for a 40% decline in kidney function over a 5 year period, as per KidneyIntelX's intended use, we can guide early intervention, resulting in better outcomes.